市場調查報告書
商品編碼
964919

囊性纖維化(CF)的治療市場-增長,趨勢和預測(2020-2025)

Cystic Fibrosis (CF) Therapeutics Market- Growth, Trends, and Forecast (2020 - 2025)

出版日期: | 出版商: Mordor Intelligence Pvt Ltd | 英文 111 Pages | 商品交期: 2-3個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

預計在預測期內,囊性纖維化藥物的市場規模將以9.1%的複合年增長率增長。囊性纖維化(CF)的患病率增加,再加上治療率的提高,是有望促進囊性纖維化藥物市場增長的重要因素。此外,預計在未來幾年中,非營利組織的更多努力,私人和公共機構的研發資金的增加以及政府的嚴格監管將推動市場的發展。

根據囊性纖維化基金會發佈的數據,這種遺傳性疾病的發病率正在不斷增加。在2019年,將有超過70,000名患者患有囊性纖維化。隨著患者人數逐年增加,對有效的和有效的治療劑的需求進一步增加。

潛在的臨床候選藥物的增加也是預期推動市場增長的關鍵因素之一。此外,在現有藥物組合中擴大目標患者群的臨床試驗數量激增也是該市場的驅動力。擴大研發活動有望促進市場增長。管線中的藥物包括Symdeko(tezacaftor + ivacaftor),VX-561,ELX-02,ABBV-3067。

持續參與與囊性纖維化相關活動的各種非營利組織,例如全球囊性纖維化,囊性纖維化基金會,加拿大囊性纖維化基金會,南非囊性纖維化基金會和南非囊性纖維化協會的存在也在迅速增加。這是滿足需求的重要因素之一。這些組織投入大量資金來尋找治療囊性纖維化的不同方法,並支持著名企業的研發活動。但是,高昂的治療費用有望抑制市場增長。

該報告調查了囊性纖維化(CF)藥物市場,提供了該市場的概述,按藥物類別,給藥途徑,地區和進入市場的公司概況的趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第4章市場動態

  • 市場概況
  • 市場驅動力
    • 囊性纖維化的患病率增加
    • 嚴格的政府法規
    • 潛在的臨床候選藥物增加
  • 市場限制
    • 重磅炸彈和非專利藥專利已過期
    • 高昂的疾病治療費用
  • 波特的五力分析

第5章市場細分

  • 按毒品類別
    • 胰□補充劑
    • 粘液溶解劑
    • 支氣管擴張器
    • CFTR調節器
  • 按照管理途徑
    • 口服藥物
    • 吸入劑
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東/非洲
    • 南美洲
    • 巴西
    • 阿根廷
    • 其他

第6章競爭情況

  • 公司簡介
    • AbbVie Inc.
    • Alaxia
    • Allergan
    • AstraZeneca
    • Beyond Air Inc.
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences Inc.
    • Mylan NV
    • Teva Pharmaceutical Industries Ltd
    • Vertex Pharmaceuticals Incorporated

第7章 市場機會與將來動向

目錄
Product Code: 68417

The cystic fibrosis therapeutics market is anticipated to register a CAGR of nearly 9.1% during the forecast period. The increasing prevalence of cystic fibrosis (CF), coupled with the rising treatment rate, is one of the key factors expected to bode well for the market growth for these therapeutics. Moreover, a rising number of initiatives undertaken by nonprofit organizations, an increase in R&D funding by both private and public organizations, and supportive government legislation are some of the crucial factors expected to drive the market in the coming few years.

According to the data published by the Cystic Fibrosis Foundation, the incidence of these hereditary disorders is constantly growing. In 2019, there were more than 70,000 patients are living with cystic fibrosis. Increasing year-on-year growth in the number of patients further results in surging demand for efficient and effective CF therapeutics.

The rising number of potential clinical pipeline candidates is one of the key factors expected to propel the market growth. Moreover, upsurge in the number of clinical trials to expand its target patient base with the existing drug portfolio is also amongst some of the drivers of this market. Growing R&D activities are expected to propel market growth. Some of the pipelined drugs are Symdeko (tezacaftor + ivacaftor), VX-561, ELX-02 and ABBV-3067.

The presence of various nonprofit organizations, such as Cystic Fibrosis Worldwide, Cystic Fibrosis Foundation, Cystic Fibrosis Canada, South African Cystic Fibrosis Trust, and South African Cystic Fibrosis Association, which are consistently involved in the activities related to CF is also one of the pivotal factors that can be accounted for surging demand. These organizations are investing huge amount of funds to find various therapeutics for CF and to support the research and developmental activities by prominent players. However, high cost of the treatment may restrain the growth of the market.

Key Market Trends

CFTR Modulators Dominates the Market and is Expected to Continue to Do the Same during the Forecast Period

CFTR modulators are expected to dominate the cystic fibrosis therapeutics market through the forecast period. This can be attributed to new product launch, high commercial availability, and huge demand for these drugs to treat CF are expected to drive the segment. These modulators are designed to correct the malfunctioning protein made by the CFTR gene. For instance, recently launched ORKAMBI lead the way for segmental growth. This drug class directly cures the underlying cause of the disease.

Thus, the CFTR modulators segment is witnessing a shift toward combination therapies that provide enhanced results to patients. Higher availability, positive results, and reimbursement policies by key players for the target disease are supplementing the growth of the segment. Focus on developing new drugs to address the changing needs of the patients, such as TRIKAFTA and KALYDECO, in the treatment poised to create a significant shift in prescription patterns.

North America Represents the Largest Market and Asia-Pacific is Expected to Register Fastest Growth.

North America is at the forefront of growth in the region and is also an important revenue contributor in the global arena. Heightened awareness of disease remittance therapies among patients, rising prevalence of CF, and high public and private healthcare spending are stimulating the growth of the region. The United States has most of the people affected with CF who are of Caucasian descent. Furthermore, initiatives taken by CF Foundation and Cystic Fibrosis Canada are one of the key reasons that can be accounted for its largest share. Moreover, easy access to quality healthcare, favorable reimbursement policies, strong clinical pipeline, and approval of novel drugs are projected to promote revenue growth in North America.

The Asia-Pacific is likely to witness the fastest growth throughout the forecast period. The growing adoption of the urban lifestyle is leading to expanding the base of patients in the region. This, coupled with increasing healthcare spending, is expected to propel the market in APAC. Favorable regulatory policies for biosimilars are estimated to boost demand for the regional market over the forecast period.

Competitive Landscape

The key players are consistently involved in the development of new or combination of products to treat cystic fibrosis. Investment in the R&D is one of the strategic measures to beat the competition. The key players in this market are AbbVie Inc.; F. Hoffmann-La Roche Ltd; Gilead; Novartis AG; Vertex Pharmaceuticals Inc.; AIT (Advanced Inhalation Therapies); Alaxia; Teva Pharmaceutical Industries Ltd; Merck & Co. Inc.; Alcresta Therapeutics Inc.; Allergan; and AstraZeneca.

The players operating in the market focus on introducing new products to address the changing needs of the patients. For instance, in April 2019, the US Food and Drug Administration (FDA) approved Vertex Pharmaceuticals Incorporated's KALYDECO (ivacaftor) with an aim of expanding the range of treatment options for the millions of children living with cystic fibrosis (CF). This allows physicians to begin treating the underlying cause of CF in eligible infants as young as six months of age for the first time, with the potential to modify the course of the disease.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Cystic Fibrosis
    • 4.2.2 Supportive Government Legislation
    • 4.2.3 Increase in Potential Clinical Pipeline Candidates
  • 4.3 Market Restraints
    • 4.3.1 Patent Expiration of Blockbuster and Generic Drugs
    • 4.3.2 High Cost of Disease Treatment
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Drug Class
    • 5.1.1 Pancreatic Enzyme Supplements
    • 5.1.2 Mucolytics
    • 5.1.3 Bronchodilators
    • 5.1.4 CFTR Modulators
  • 5.2 By Route of Administration
    • 5.2.1 Oral Drugs
    • 5.2.2 Inhaled Drugs
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle-East and Africa
    • 5.3.5 South America
    • 5.3.6 Brazil
    • 5.3.7 Argentina
    • 5.3.8 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 AbbVie Inc.
    • 6.1.2 Alaxia
    • 6.1.3 Allergan
    • 6.1.4 AstraZeneca
    • 6.1.5 Beyond Air Inc.
    • 6.1.6 F. Hoffmann-La Roche Ltd
    • 6.1.7 Gilead Sciences Inc.
    • 6.1.8 Mylan NV
    • 6.1.9 Teva Pharmaceutical Industries Ltd
    • 6.1.10 Vertex Pharmaceuticals Incorporated

7 MARKET OPPORTUNITIES AND FUTURE TRENDS